Forte Biosciences, Inc.
FBRXNasdaq
$48.86
↑ +8.6%Jul 17 close · end-of-day
Price
1Y↑ +404.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$75.9M
Free Cash Flow (TTM)
-$59.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-180.2%
ROIC
—
Debt / Equity
—
Net Cash
$58.2M
Return 1Y
+390.6%
Company profile
Forte Biosciences is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
- CEO
- Paul A. Wagner
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- Texas
- Website
- fortebiorx.com
Management & directors
- Riley Antony ACHIEF FINANCIAL OFFICER
- Wagner Paul A.SEE REMARKS
Roles derived from SEC Form 4 filings.
Earnings
FBRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.24↓ -9.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$46.3M | -$21.5M | -$13.9M | -$32.5M | -$36.6M | -$70.7M |
| Net income | -$46.5M | -$21.7M | -$13.9M | -$31.5M | -$35.5M | -$69.4M |
| Diluted EPS | — | -$1.55 | -$0.80 | -$24.92 | -$12.17 | -$4.71 |
| Operating cash flow | -$18.4M | -$16.7M | -$8.2M | -$28.7M | -$30.7M | -$50.9M |
| Free cash flow | — | — | — | -$28.8M | -$30.8M | -$51.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.8M | -$8.6M | -$7.4M | -$16.1M | -$11.6M | -$18.4M | -$24.6M | -$22.4M |
| Net income | -$12.5M | -$8.4M | -$7.2M | -$15.7M | -$11.2M | -$17.7M | -$24.8M | -$22.1M |
| Diluted EPS | -$6.78 | -$4.54 | $3.18 | -$1.37 | -$0.96 | -$0.99 | -$1.39 | -$1.24 |
| Operating cash flow | -$5.9M | -$8.1M | -$10.0M | -$10.4M | -$10.1M | -$14.0M | -$16.5M | -$18.8M |
| Free cash flow | -$5.9M | -$8.1M | -$10.0M | -$10.4M | -$10.1M | -$14.1M | -$16.5M | -$18.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 10, 2026
Jul 9, 2026
- 11d agoForte Biosciences shares surge after positive phase 1b vitiligo resultsproactiveinvestors.com
- 11d agoFBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally?stocktwits.com
- 11d agoForte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Studyfinance.yahoo.com
- 11d agoForte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX)investorshub.advfn.com
- 11d agoEnovix, Forte Biosciences rally premarket; PepsiCo slipsfinance.yahoo.com
- 11d agoFB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Periodfinance.yahoo.com
Jun 13, 2026
May 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Tax withholding | 134 | $21.32 | $2,856.88 | filing |
| 2026-07-01 | Wagner Paul A.· SEE REMARKS | Tax withholding | 98 | $21.32 | $2,089.36 | filing |
| 2026-07-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Option exercise | 375 | — | — | filing |
| 2026-07-01 | Wagner Paul A.· SEE REMARKS | Option exercise | 1,250 | — | — | filing |
| 2026-04-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Tax withholding | 134 | $24.86 | $3,331.24 | filing |
| 2026-04-01 | Wagner Paul A.· SEE REMARKS | Tax withholding | 98 | $24.86 | $2,436.28 | filing |
| 2026-04-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Option exercise | 375 | — | — | filing |
| 2026-04-01 | Wagner Paul A.· SEE REMARKS | Option exercise | 1,250 | — | — | filing |
| 2026-01-01 | Wagner Paul A.· SEE REMARKS | Tax withholding | 164 | $27.27 | $4,472.28 | filing |
| 2026-01-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Tax withholding | 154 | $27.27 | $4,199.58 | filing |
| 2026-01-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Option exercise | 375 | $0.00 | $0.00 | filing |
| 2026-01-01 | Wagner Paul A.· SEE REMARKS | Option exercise | 1,250 | $0.00 | $0.00 | filing |
| 2025-12-30 | Riley Antony A· CHIEF FINANCIAL OFFICER | Buy | 9,680 | $26.33 | $254,832.78 | filing |
| 2025-10-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Tax withholding | 134 | $14.52 | $1,945.68 | filing |
| 2025-10-01 | Wagner Paul A.· SEE REMARKS | Tax withholding | 98 | $14.52 | $1,422.96 | filing |
| 2025-10-01 | Wagner Paul A.· SEE REMARKS | Option exercise | 1,250 | $0.00 | $0.00 | filing |
| 2025-10-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Option exercise | 375 | $0.00 | $0.00 | filing |
| 2025-07-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Tax withholding | 134 | $12.44 | $1,666.96 | filing |
| 2025-07-01 | Wagner Paul A.· SEE REMARKS | Tax withholding | 98 | $12.44 | $1,219.12 | filing |
| 2025-07-01 | Riley Antony A· CHIEF FINANCIAL OFFICER | Option exercise | 375 | $0.00 | $0.00 | filing |
| 2025-07-01 | Wagner Paul A.· SEE REMARKS | Option exercise | 1,250 | $0.00 | $0.00 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.